TCON vs. FNCH, TCBP, ALBT, GMDAQ, KRBP, PALI, ELOX, WINT, FRTX, and TTNP
Should you be buying TRACON Pharmaceuticals stock or one of its competitors? The main competitors of TRACON Pharmaceuticals include Finch Therapeutics Group (FNCH), TC Biopharm (TCBP), Avalon GloboCare (ALBT), Gamida Cell (GMDAQ), Kiromic BioPharma (KRBP), Palisade Bio (PALI), Eloxx Pharmaceuticals (ELOX), Windtree Therapeutics (WINT), Fresh Tracks Therapeutics (FRTX), and Titan Pharmaceuticals (TTNP). These companies are all part of the "biological products, except diagnostic" industry.
TRACON Pharmaceuticals (NASDAQ:TCON) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
TRACON Pharmaceuticals currently has a consensus target price of $60.00, suggesting a potential upside of 3,900.00%. Given TRACON Pharmaceuticals' higher probable upside, equities research analysts clearly believe TRACON Pharmaceuticals is more favorable than Finch Therapeutics Group.
11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Finch Therapeutics Group's return on equity of -68.11% beat TRACON Pharmaceuticals' return on equity.
TRACON Pharmaceuticals received 256 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 58.46% of users gave TRACON Pharmaceuticals an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
TRACON Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
TRACON Pharmaceuticals has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, TRACON Pharmaceuticals had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for TRACON Pharmaceuticals and 3 mentions for Finch Therapeutics Group. TRACON Pharmaceuticals' average media sentiment score of 1.25 beat Finch Therapeutics Group's score of 0.95 indicating that TRACON Pharmaceuticals is being referred to more favorably in the media.
Summary
TRACON Pharmaceuticals beats Finch Therapeutics Group on 12 of the 16 factors compared between the two stocks.
Get TRACON Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TRACON Pharmaceuticals Competitors List
Related Companies and Tools
